Master Protocol of Two Independent, Randomized, Double-Blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants with Relapsing Forms of Multiple Sclerosis

This project is being done to assess the efficacy and safety of frexalimab in comparison to one of the usual treatments, teriflunomide, in reducing the relapse frequency and in slowing the progression of disability in RMS, over time.